# Cellectis (CLLS) — News

CLLS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/clls/news

## Recent headlines

- [Qatar fuel - Overall sales volume recorded a 14% decrease in 9-months](https://www.ainvest.com/news/qatar-fuel-sales-volume-recorded-14-decrease-9-months-2610) — AInvest Wire, Oct 14, 2026
  Qatar Fuel (QSE: QFLS) reported a 14% decline in overall sales volume over the first nine months of 2026, according to recent data. This marks a notable shift from previous performance, as the company had experienced robust growth in recent years. For instance, in FY 2025, the company recorded…
- [Cellectis SA: Barclays cuts to underweight from overweight; cuts target price to $1.3 from $9](https://www.ainvest.com/news/cellectis-sa-barclays-cuts-underweight-overweight-cuts-target-price-1-3-9-2609) — AInvest Wire, Sep 16, 2026
  Barclays has revised its stance on Cellectis SA (NASDAQ: CLLS), downgrading the stock from overweight to underweight and lowering its price target from $9 to $1.30. The move reflects a shift in the firm’s assessment of the company’s outlook and market positioning. Previously, Barclays had initiated…
- [Cellectis announces strategic transformation to in vivo gene editing company](https://www.ainvest.com/news/cellectis-announces-strategic-transformation-vivo-gene-editing-company-2609) — AInvest Wire, Sep 14, 2026
- [Cellectis to host conference call and webcast on September 14 to provide a business update](https://www.ainvest.com/news/cellectis-host-conference-call-webcast-september-14-provide-business-update-2609) — AInvest Wire, Sep 11, 2026
  Cellectis (Euronext Growth: ALCLS - NASDAQ: CLLS) is set to host a conference call and webcast on September 14, 2026, to provide a business update to investors and stakeholders. The call will be part of the company’s ongoing engagement with the investment community, following its participation in…
- [Cellectis - final Phase 1 Balli-1 data for Lasme-Cel to be presented June 13, 2026](https://www.ainvest.com/news/cellectis-final-phase-1-balli-1-data-lasme-cel-presented-june-13-2026-2606) — AInvest Wire, Jun 9, 2026
  Cellectis, a clinical-stage biotechnology company, is set to present final Phase 1 data for its CD22-directed allogeneic CAR-T therapy, Lasme-cel, at the EHA annual congress on June 13 . The data will be presented orally by Nitin Jain, M.D., from MD Anderson Cancer Center, during a session on…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).